Askin tumor is a rare disease which had previously been reported as being thallium-201 and gallium-67 avid.
CASE REPORT
In this case, a 17 year old girl with a past medical history of scoliosis, cerebral palsy and developmental delay presented with shortness of breath. A subsequent chest radiograph (figure 1) and contrast enhanced chest CT (figure2A and 3A) showed she had a large intrathoracic mass which was heterogeneously enhancing and arising from the chest wall. No calcifications were identified in the mass on CT. The mass was biopsied during the admission and histology demonstrated small round blue cells consistent with Primitive neuroectodermal tumor (PNET) of the chest wall (figure 4). Additionally, immunohistochemical staining was positive for CD-99 ( figure 4B ).
An F18-FDG PET study using coincidence imaging with gamma camera was then performed to further characterize the lesion which showed the lesion not to be hypermetabolic ( figure 3B ). An In111-pentetrotide (figure 2B) and Tc99m-MIBI (figure 5 A & B) exam was also performed and the lesion demonstrated avidity for both radiopharmaceuticals. After en bloc resection of the tumor and chemotherapy, a repeat contrast enhanced chest CT (figure 6A), In111-pentetreotide (figure 6B) and Tc99m-MIBI (figure 7 A & B) scan was performed about 4 months later and demonstrated resolution of disease.
Askin tumor of the chest wall is a rare malignancy that is considered to be a PNET, which itself is now considered to be part of a spectrum of soft tissue sarcomas in the Ewing sarcoma family of tumors (EFT) [1] . These tumors have also been shown to share similar immunohistochemical properties and characteristic chromosomal translocations and, therefore, are thought to have a common cell origin [2] . The chromosomal abnormality is a reciprocal translocation between chromosomes 11 and 22 t (11;22) [3] . Despite having a similar genetic mutation, varying imaging characteristics (especially in nuclear medicine) have been reported between EFT lesions of different patients [4, 5] EFT represents the second most common primary bone malignancy affecting children and adolescents after DISCUSSION CASE REPORT osteosarcoma [6] . The reported incidence is approximately 3 per million with both sexes almost equally affected and predominantly occurring in the 20-30 year old age range [7] . Six to 15% of EFT cases are found to arise from the chest wall [8] .
Treatment for Askin tumor is generally a multidisciplinary endeavor with use of chemotherapy, surgery and external beam radiation therapy [7] . The prognosis of Askin tumor is poor with one case series of 104 patients with the disease that showed survival median survival at 28 months to be 45% [7] . The clinical features of Askin tumor include painless swelling, painful mass, dyspnea and chest wall pain without mass [7] .
On imaging, Askin tumor can be seen on radiographs as a large unilateral extrapulmonary mass [9] . Contrast enhanced CT often shows a heterogeneous mass due to hemorrhage and necrosis with calcification being a rare finding [10] . On MRI, the lesion is often heterogeneous signal on T1 with hemorrhagic areas in the tumor demonstrating higher signal, and cystic or necrotic components in the tumor having higher signal on T2 weighting; there is often avid enhancement after IV gadolinium is administered [10] . In nuclear medicine imaging, a case report has described Askin tumor to be Ga-67 and Tl-201 avid prior to therapy with Tl-201 being a better marker for follow up exams to detect disease recurrence [11] .
There is very little literature about nuclear medicine imaging of Askin tumor and, to our knowledge, no literature related to use of In111-pentetreotide imaging of the tumor prior to this paper.
This case demonstrates nuclear scintigraphy imaging findings of Askin tumor that could help define future imaging guidelines for this rare malignancy.
In this case Tc99m-MIBI and In111-pentetrotide, scans were both positive prior to the patient receiving treatment. Subsequent Tc99m-MIBI and In111-pentetrotide scans were negative after the tumor was treated with chemotherapy and surgically resected. Previous use of Tc99m-MIBI and In111-pentetrotide to image Ewing sarcoma showed in a case report that metastatic lesions to the lung had uptake of Tc99m-MIBI and variable uptake of In111-pentetrotide [12] . Another case series showed that Tc99m-MIBI had variable uptake in Ewing sarcoma of the bone, and the presence or absence of uptake was not useful for prognostic value [13] . Specific to Askin tumor, a previous case report had shown that Thallium-201 and Gallium-67 were potential radiopharmaceutical agents that could potentially be used to image the lesion [11] .
Interestingly, the tumor in this case did not show hypermetabolism on F18-FDG PET prior to treatment. The literature is more variable regarding the use of F18-FDG to image EFT lesions. A case of extraskeletal EFT in the upper extremity [5] reported F18-FDG hypometabolism while another article reported a case of Askin tumor which demonstrated F18-FDG hypermetabolism [4] . Others have reported F18-FDG hypermetabolism in PNET of the soft tissues of the lower extremity [14] , skeleton [15] , spinal cord [16] , stomach [17] , and retroperitoneum [18] . One hypothesis of FDG hypometabolism in EFT may be that some particular lines of the tumor may underexpresses GLUT 1 cell membrane transporters [5] .
In addition to Askin tumor, the differential diagnosis for a chest wall mass includes neuroblastoma, soft tissue sarcoma, lymphoma and infection. Although the MRI and CT imaging of an Askin tumor and neuroblastoma may overlap, the majority of neuroblastomas demonstrate positivity on I123-MIBG scans which can potentially help differentiate the two. In a soft tissue sarcoma such as a rhabdomyosarcoma, the lesion should be isodense and isointense to muscle on CT and MRI respectively.
Osteosarcomas should be F18-FDG positive and may have increased uptake on Tc99m-MIBI, Ga-67 and Tl-201 scinitigraphy as well. An infection would present with more classic clinical findings such as fever and leukocytosis. Lymphomas of the chest wall might also present with similar radiologic findings as an Askin tumor and would be difficult to differentiate based on imaging alone.
In conclusion, we report a case of Askin tumor in a 17 year old patient which demonstrates In111-pentetreotide and Tc99m-MIBI avidity prior to treatment and resolution of activity after treatment. Additionally, the lesion was F18-FDG hypometabolic.
Askin tumors can be Tc99m-MIBI and In111-pentetrotide avid and use of these radiopharmaceuticals can also be used to assess for disease response to treatment.
Despite the aggressive nature of Askin tumor, F18-FDG PET imaging is variable and does not necessarily show hypermetabolism in all cases. Nuclear Medicine: Nuclear scintigraphy findings for Askin tumor with In111-pentetreotide, Tc99m-MIBI and F18-FDG.
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